The VanEck Vectors Gold Miners ETF traded higher Thursday after billionaire George Soros said he bought gold and gold miners.
CNBC's Dominic Chu reports on bearish comments on gold by George Soros and Carl Icahn.
Carl Icahn and Bill Ackman may have made up after their epic feud, but Icahn still insists Ackman is "totally wrong" for shorting Herbalife.
Billionaire investor Carl Icahn joined CNBC's "Squawk Box" on Thursday to share his investment outlook and stock strategy.
The billionaire investor says he still thinks very highly of Apple, but remains concerned about its prospects in China.
"I don't think anybody who supports Donald is happy" with Trump's comment about a Mexican-American judge, Icahn told CNBC.
Carl Icahn says bearish bets by George Soros have some merit because the stock market has been artificially boosted by prolonged low interest rates.
Billionaire investor Carl Icahn, who made up with Ackman, tells CNBC Herbalife is not a pyramid scheme and it creates jobs.
I would get back into Apple if I felt more secure abut China, says Carl Icahn, Icahn Enterprises, sharing his thoughts on the tech giant.
Carl Icahn, Icahn Enterprises shares his thoughts on Donald Trump's run for the White House.
Carl Icahn, Icahn Enterprises, discusses how he makes philanthropic decisions, including education and the medical community.
In a wide-ranging conversation, Carl Icahn, Icahn Enterprises, talks to the "Squawk Box" crew about medical philanthropy, George Soros' gold play, market valuations
Carl Icahn, Icahn Enterprises, weighs in on stock valuations.
Billionaire investor Carl Icahn boosted his stake in Hertz Global Holdings to 15.24 percent from 14.34 percent, according to a SEC filing.
Take a look at some of Tuesday's early movers: RL, HTZ, ZG, GDDY, BIIB, VRX & more
Allergan CEO Brent Saunders tells CNBC's "Squawk on the Street" why attention from famed activist investor Carl Icahn's is a stamp of approval.
Ratings firm Moody's believes investors are going to continue to pressure Prudential and AIG into trying to get off the SIFI list as well.
Les Funtleyder, Esquared Asset Management, discusses Carl Icahn's large position in Allergan and investing in biotech.
David Maris, Wells Fargo, discusses Carl Icahn's new stake in Allergan.
The activist investor expresses support and confidence in Allergan CEO Brent Saunders.